Dobutamine Infusion Rate Calculation
For a 70-kg patient requiring 3 µg/kg/min of dobutamine from a 500 mg in 250 mL solution (2 mg/mL concentration), set the pump to 6.3 mL/h.
Calculation Method
The calculation follows this straightforward approach:
Step 1: Calculate the required dose in µg/min
- 3 µg/kg/min × 70 kg = 210 µg/min
Step 2: Convert to mg/min
- 210 µg/min ÷ 1000 = 0.21 mg/min
Step 3: Convert to mg/h
- 0.21 mg/min × 60 min = 12.6 mg/h
Step 4: Calculate infusion rate based on concentration
- Concentration = 2 mg/mL (500 mg in 250 mL)
- Infusion rate = 12.6 mg/h ÷ 2 mg/mL = 6.3 mL/h
Clinical Context from Guidelines
The ESC Heart Failure Guidelines 1 recommend starting dobutamine at 2.5 µg/kg/min and doubling the dose every 15 minutes according to response or tolerability, with dose titration typically limited by excessive tachycardia, arrhythmias, or ischemia. A dose >20 µg/kg/min is rarely needed. Your target of 3 µg/kg/min represents an appropriate starting dose slightly above the minimum recommended threshold.
The FDA label 2 confirms that optimal infusion rates typically range from 2-20 µg/kg/min, though rates up to 40 µg/kg/min have occasionally been required. The label provides comprehensive dosing tables for various concentrations and patient weights.
Monitoring Requirements
Close monitoring is essential 1:
- Symptoms and heart rate/rhythm
- Systemic blood pressure
- Urine output (target >100 mL/h in first 2 hours)
- Oxygen saturation if hypoxemic
Titration should be guided by clinical response, including reduction in dyspnea, adequate diuresis, improvement in peripheral perfusion (skin temperature, color), and reduction in heart and respiratory rates, which should occur within 1-2 hours 1.
Important Safety Considerations
Dobutamine has potential adverse effects including tachycardia, arrhythmias, hypotension (due to mild vasodilator activity from β2-adrenoceptor stimulation), and ischemia 1, 3. The 2022 AHA/ACC/HFSA Guidelines 3 emphasize that long-term use of continuous intravenous inotropes is potentially harmful except as bridge therapy to advanced therapies or for palliative care.
Pharmacokinetic variability is substantial in critically ill patients 4, with clearance changes ranging from 72% decrease to 88% increase, particularly during the first 24 hours of therapy. This underscores why infusion rates should be guided by clinical endpoints rather than predetermined values 4.